(Q33346713)

26 July 2017

title

Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma (English)

1 reference

malignant pleural mesothelioma

26 July 2017

main subject

1 reference

1 reference

1 reference

1 reference

A Bakhshandeh

1

1 reference

26 July 2017

I Bruns

2

1 reference

26 July 2017

A Traynor

3

1 reference

26 July 2017

H I Robins

4

1 reference

26 July 2017

K Eberhardt

5

1 reference

26 July 2017

A Demedts

6

1 reference

26 July 2017

E Kaukel

7

1 reference

26 July 2017

G Koschel

8

1 reference

26 July 2017

U Gatzemeier

9

1 reference

26 July 2017

Th Kohlmann

10

1 reference

26 July 2017

K Dalhoff

11

1 reference

26 July 2017

E M Ehlers

12

1 reference

26 July 2017

Y Gruber

13

1 reference

26 July 2017

R Zumschlinge

14

1 reference

26 July 2017

S Hegewisch-Becker

15

1 reference

26 July 2017

S O Peters

16

1 reference

26 July 2017

G J Wiedemann

17

1 reference

26 July 2017

publication date

1 March 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

39

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

339-345

1 reference

The epidemiology of mesothelioma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Status of clinical hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Modulation of VP-16 cytotoxicity by carboplatin and 41.8 degrees C hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

A new technological approach to radiant heat whole body hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

The role of gemcitabine in the treatment of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900536-6

7 January 2021

10.1016/S0169-5002(02)00536-6

Identifiers

DOI

1 reference

26 July 2017

1 reference